Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [3]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and business practices [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between November 4, 2024, and October 3, 2025, and aims to address alleged misleading statements made by the company regarding its product, nimacimab [1][5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Skye Bioscience - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business operations and the effectiveness of nimacimab, which were overstated [5]. - Specific allegations include that nimacimab was less effective than claimed, and that the company's clinical, regulatory, and commercial prospects were misrepresented [5]. Group 3: Legal Representation - Investors interested in joining the class action can do so by contacting Rosen Law Firm through their website or phone [3][6]. - It is noted that no class has been certified yet, and investors are advised they may select their own counsel or remain absent from the class [7]. Group 4: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in terms of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. about a class action lawsuit related to misleading statements regarding the company's lead product candidate, nimacimab, which allegedly had overstated effectiveness and prospects [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and its clinical, regulatory, and commercial prospects [3]. - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost to participate [4]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/? ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the specified Class Period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's defendants misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 21 ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of securities laws, specifically related to misleading statements about its drug candidate, nimacimab, and its commercial prospects [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Skye's securities between November 4, 2024, and October 3, 2025, and encourages them to contact the Schall Law Firm before January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the effectiveness of nimacimab and overstated its commercial and clinical prospects [4]. Group 2: Investor Impact - Investors suffered damages when the truth about Skye's drug candidate and its market position was revealed [4]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities between November 4, 2024, and October 3, 2025, due to alleged misleading statements regarding the company's business and product effectiveness [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Skye Bioscience made materially false and misleading statements about its product nimacimab, asserting that it was less effective than represented, which overstated its clinical and commercial prospects [5]. - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].